Evidence map›Paper›PMID 41895717›Full record

Trial reportJournal for immunotherapy of cancer2026

CD8 PET imaging with [

Michael A Postow, Peter D Zang, Sumanta K Pal, Audrey Mauguen, Michael Farwell, Michael Gordon, David Hays, Jeffrey Y C Wong, Delphine Chen, Gary A Ulaner and 25 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Michael A Postow *Memorial Sloan Kettering Cancer Center, New York, New York, USA postowm@mskcc.org.ORCID http://orcid.org/0000-0002-3367-7961
Peter D Zang *Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Sumanta K Pal *City of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID http://orcid.org/0000-0002-1712-0848
Audrey MauguenEpidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael FarwellDivision of Nuclear Medicine and Molecular Imaging, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael GordonHonorHealth, Scottsdale, Arizona, USA.
David HaysCARTI Cancer Center, Little Rock, Arkansas, USA.
Jeffrey Y C WongDepartment of Radiation Oncology, City of Hope Beckman Research Institute and Medical Center, Duarte, California, USA.
Delphine ChenUniversity of Washington, Seattle, Washington, USA.
Gary A UlanerDepartment of Molecular Imaging Departments of Radiology and Translational Genomics, Therapy Hoag Family Cancer Institute, Irvine Los Angeles, California, USA.
Giuseppe EspositoMedStar Georgetown University Hospital, Washington, DC, USA.
Jonathan McConathyUniversity of Alabama at Birmingham Health System Authority, Birmingham, Alabama, USA.
Michael M GrahamDepartment of Radiology, University of Iowa, Iowa city, Iowa, USA.
Anthony F ShieldsKarmanos Cancer Institute, Detroit, Michigan, USA.
Annick D Van den AbbeeleDepartment of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Marcus O ButlerPrincess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Jacob S ThomasUSC Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Przemyslaw TwardowskiDepartment of Urologic Oncology, Providence Saint John's Health Center, Santa Monica, California, USA.
Jayant NarangTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Aman P SinghOncology Cell Therapy and Therapeutic Area Unit, Waltham, Massachusetts, USA.
Agnish DeyOncology Cell Therapy and Therapeutic Area Unit, Waltham, Massachusetts, USA.
Kevin P MarescaWRDM, Pfizer Inc, Tewksbury, Massachusetts, USA.
Edmund KeliherPfizer Inc, New York, New York, USA.
Feng LiuClinical Pharmacology and Translational Sciences, Pfizer Oncology Division, La Jolla, California, USA.
Guillaume PotdevinAstraZeneca US, Wilmington, Delaware, USA.
Guenter SchmidtAstraZeneca US, Wilmington, Delaware, USA.
William LeImaginAb Inc, Inglewood, California, USA.
Ian WilsonImaginAb Inc, Inglewood, California, USA.
Alessandro MascioniImaginAb Inc, Inglewood, California, USA.
Fang JiaImaginAb Inc, Inglewood, California, USA.
Ronald KornRadiology, Imaging Endpoints, Scottsdale, Arizona, USA.
Michael R FerrisImaginAb Inc, Inglewood, California, USA.
Kristin SchmiedehausenImaginAb Inc, Inglewood, California, USA.
Neeta Pandit-TaskarMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Kim A MargolinMedical Oncology, City of Hope National Medical Center, duarte, California, USA.ORCID http://orcid.org/0000-0002-5248-4356

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundCD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [

methodsThe Phase II, prospective multicenter study (iCorrelate) tested the correlation between CD8 PET and CD8 cells by IHC of core needle biopsies from patients with solid tumors receiving immune checkpoint blockade. The safety of repeat CD8 PET was additionally analyzed.

results49 patients had 70 biopsies (37 baseline and 33 on-treatment) for correlating CD8 PET with IHC. Standard uptake value mean of the biopsied tumor normalized to aorta showed a correlation with IHC of 0.49 (95% CI 0.26 to 0.59). The correlation was 0.71 (95% CI 0.48 to 0.85) in patients with renal cell carcinoma. Repeat CD8 PET imaging on-treatment was safe.

conclusionsWe found a modest correlation between CD8 PET with [

Indexed as

CD8-Positive T-LymphocytesNeoplasmsPositron-Emission TomographyRadioisotopesZirconiumAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesRadioisotopesZirconiumZirconium-89BiopsyImmune Checkpoint InhibitorImmunotherapyIntratumoralT cell

Identifiers

PMID41895717
PMCPMC13034240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.